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Abstract
Background/Objectives—U.S.-born non-Hispanic black (blacks) persons (12% of U.S. 
population) accounted for 41% of HIV diagnoses during 2008–2014. HIV significantly increases 
TB and TB-related mortality. TB rate ratios were 6–7 times as high in blacks versus U.S.-born 
non-Hispanic whites (whites) during 2013–2016. We analyzed a sample of black and white TB 
patients to assess the impact of HIV on TB racial disparities.
Methods—552 black and white TB patients with known HIV status were recruited from 10 U.S. 
sites in 2009–2010. We abstracted data from the National TB Surveillance System, medical 
records, and death certificates, and interviewed 477 patients. We estimated adjusted odds ratios 
(AOR) with 95% confidence intervals (CI) for associations of with HIV infection, late HIV 
diagnosis (≤ 3 months before or any time after TB diagnosis), and mortality during TB treatment.
Results—Twenty-one percent of the sample had HIV. Blacks (AOR=3.4, CI=1.7–6.8), and 
persons with recent homelessness (AOR=2.5, CI=1.5–4.3) had greater odds of HIV than others. 
The majority of HIV/TB patients were diagnosed with HIV ≤ 3 months before (57%) or after (4%) 
TB diagnosis. Among HIV/TB patients, blacks had similar percentages to whites (61% versus 
57%) of late HIV diagnosis. Twenty-five percent of HIV/TB patients died, 38% prior to TB 
diagnosis and 62% during TB treatment. Blacks did not have significantly greater odds of TB-
related mortality than whites (AOR=1.1, CI=.6–2.1).
Conclusions—Black TB patients had greater HIV prevalence than whites. While mortality was 
associated with HIV, it was not significantly associated with black or white race.
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U.S.-born non-Hispanic black TB patients had greater HIV prevalence than whites. Sixty percent 
of study patients were diagnosed with HIV near the time of TB diagnosis. While mortality was 
associated with HIV, it was not significantly associated with black race.
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While the United States reduced tuberculosis (TB) rates among nearly all demographic 
groups in the United States, disparities still exist. Among 4,331 U.S.-born cases in 2010, 
(39% of TB cases reported to the U.S. Centers for Disease Control and Prevention’s [CDC] 
National TB Surveillance System [NTSS]), non-Hispanic black or African Americans 
(blacks) had the greatest TB burden: blacks accounted for 41% of U.S.-born TB cases, 
followed by 33% for non-Hispanic whites (whites).1 While this percentage dropped to 37% 
in 2016, TB black/white rate ratios were consistently six to seven times as high from 2013–
2016; in 2016, TB incidence was 3.0 cases per 100,000 blacks, compared with 0.5 per 
100,000 whites.2
Blacks are also disproportionately affected by HIV infection, which significantly increases 
the risk for progression to TB after TB exposure and for TB-related mortality.3 During 
2008–2014, U.S.-born blacks accounted for approximately 41% of HIV diagnoses,4,5 and, 
during 2008–2014 (excluding California and Vermont, which didn’t report HIV/TB data to 
the NTSS during the period) made up 73% of U.S.-born TB cases with reported HIV.6 HIV 
testing of TB patients is recommended practice, with HIV status reported for 77% of all TB 
cases during 2008–2014, and for 84% of TB cases aged 25–44 years.1 As a percentage of 
U.S.-born TB cases during 2008–2014, 16% of blacks, but only 7% of Hispanics, 4% of 
whites, 3% of American Indian/Alaskan Natives, and 1% of Asians had HIV infection.6 
Figure 1 shows the percentage of reported HIV comorbidity among U.S.-born non-Hispanic 
whites and blacks with TB during 1994–2016. Although rates of concomitant HIV and TB 
among U.S.-born persons have dropped dramatically among blacks over the past two 
decades, they were more than 17 times as high in 2016 as those of whites (See Supplemental 
file).
One hypothesis is that delays in TB diagnosis and treatment during the infectious period 
among blacks could explain the TB disparity. This hypothesis was rejected, since a study 
evaluating delayed time to TB diagnosis as a risk factor for transmission of Mycobacterium 
tuberculosis (Mtb) from U.S.-born non-Hispanic black and white TB patients to their 
contacts found that whites actually had longer times to diagnosis than blacks.7 However, the 
same study found that persons having close contact to black TB patients were twice as likely 
to have latent TB infection as contacts to white patients.7 While reasons for this finding were 
not examined, blacks could have had greater prevalence of TB infection because of greater 
immunosuppression that makes such persons more susceptible to acquiring TB infection, or 
because of greater past TB exposure.8,9
We analyzed the above-mentioned sample to assess the impact of HIV on TB racial 
disparities. We describe characteristics of TB patients with and without HIV. Then, we 
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analyze the effect of race on timing of TB diagnosis in relation to HIV diagnosis and on TB-
related mortality.
Methods
CDC’s Division of TB Elimination funded 20 sites to participate in the Tuberculosis 
Epidemiologic Studies Consortium (TBESC-1).10 Our analysis is a sub-study of a primary 
study to assess determinants of early diagnosis, prevention and treatment of TB in U.S.-
born, non-Hispanic blacks and whites. Investigators performed two-stage sequential 
stratified sampling of reported TB cases, with seven TBESC and three collaborating sites 
having high percentages of black TB patients selected first, then black and white TB patients 
aged ≥15 reported to the NTSS from August 2009 through December 2010 selected until the 
site’s recruitment goals were reached or until the recruitment period ended, whichever came 
first. Study sites were the District of Columbia, Georgia, Maryland, New Jersey, New York 
City, North Carolina, Pennsylvania, Tennessee, Texas, and Virginia.7 Data sources included 
structured interviews with consenting patients (from December 2009 to March 2011), the 
NTSS, medical records, and death certificates (matched during and after TB treatment); all 
data were abstracted onto standardized forms. HIV infection at the time of TB diagnosis, 
from testing or by self-report, was obtained from the NTSS, medical records, and interviews; 
we used any source that indicated HIV infection or AIDS. Patients with unknown HIV status 
were not analyzed in this sub-study. Patient interviews assessed existence and timing of TB 
symptoms, date of HIV diagnosis, and HIV antiretroviral medication use. Other data 
included age, sex, education, residence in a long-term care facility, chronic illness (defined 
as diabetes, high blood pressure, kidney disease, asthma, sickle cell disease, heart disease, 
chronic obstructive pulmonary disease, cancer, rheumatoid arthritis, or silicosis), and recent 
(within the year prior to TB diagnosis) history of injecting or non-injecting substance use, of 
incarceration, and of homelessness within the past year.
Our current study further analyzed the above-mentioned sample to describe characteristics 
of TB patients with HIV, rapid TB diagnosis (using a nucleic acid amplification test, i.e., 
NAAT), late HIV diagnosis (defined as within 3 months before TB diagnosis [an AIDS 
defining illness] or any time after TB diagnosis),5 and TB-associated mortality (prior to TB 
diagnosis or during TB treatment). Mortality prior to TB diagnosis can occur when 
specimens are collected or chest radiographs conducted while the patient is alive, but results 
are obtained and the TB diagnosis is made after the patient has died. Since we hypothesized 
that black race was associated with the outcomes of HIV among the TB patients, late HIV 
diagnosis, and TB-associated mortality, we identified potential confounding variables 
associated with those outcomes and with race and entered them into multivariable logistic 
regression models. We used backwards selection to derive final models and estimate 
adjusted odds ratios (AOR) with 95% confidence intervals (CI) using SAS (version 9.4, 
Cary, NC, USA). We calculated the days from HIV to TB diagnosis among patients 
reporting their HIV diagnosis date during the interviews.
This current study is a secondary analysis of de-identified data. For the original study, the 
institutional review boards at CDC and at the local sites provided approval and patients 
provided informed consent.
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Results
At the selected sites, NTSS and medical record data were obtained for 552 U.S.-born TB 
patients having known HIV status for analysis in this study, including 426 black and 126 
white patients, and 118 persons with HIV infection. Of the 552 TB patients, death certificate 
data were found for 67 black and 21 white patients. The project team interviewed 477 
patients, including 91 with HIV infection. Some patients were interviewed prior to their 
subsequent death during TB treatment.
Characteristics of TB patients with HIV
Twenty-one percent of the sample had HIV. Blacks (AOR=3.4, CI=1.7–6.8), and persons 
with recent homelessness (AOR=2.5, CI=1.5–4.3) had greater odds, and persons aged 65 or 
older had less odds (AOR=.3, CI=.1-.6) of HIV than TB patients without the given 
characteristic (Table 1).
For the 86% of HIV/TB patients who had a tuberculin skin test (TST) or interferon gamma 
release assay (IGRA) that was documented in their medical charts, the test was less likely to 
be positive than for HIV-negative patients (OR=0.5, CI=0.3–0.8)(Table 2).
HIV patients with TB had 2.5 times the odds of having a prior episode of TB compared to 
those without HIV (OR=2.5, CI=1.1–5.6). HIV/TB patients with pulmonary disease showed 
less cavitation on chest radiography (OR=.4, CI=.3-.7) (Table 2). HIV/TB patients were 
more likely to have both pulmonary and non-pulmonary sites of TB disease (OR=3.5, 
CI=2.0–5.8) (Table 2).
Compared to HIV-negative patients, more patients with HIV/TB had reported symptoms of 
swollen lymph nodes (OR=2.8, CI=1.7–4.6), weight loss (OR=1.9, CI=1.1–3.3), or any TB 
symptom (OR=3.2, CI=1.1–9.2) (Table 2).
While 77% of HIV/TB patients were diagnosed with TB through a positive culture for Mtb 
compared with 83% of TB patients without HIV, this difference was not statistically 
significant (OR=.7, CI=.4–1.2). TB patients with HIV were no more likely to have had a 
NAAT for rapid diagnosis of TB disease than TB patients without HIV; 44% of patients with 
HIV and 48% of patients without HIV had a NAAT recorded (OR=.9, CI=.6–1.3) (Table 2). 
This was also true among 450 Mtb culture-positive patients only; overall, 52% received a 
NAAT, 49% of HIV/TB patients and 52% of TB patients without HIV (OR=.9, CI=.6–1.4).
Of HIV/TB patients who were interviewed (n=91), 63% stated they were on one or more 
HIV anti-retroviral medications at TB diagnosis, and 40% were on three or more HIV 
medications, including combination medications counted separately. There was no 
significant difference in HIV care by race (OR=1.7, CI=.4–7.2). The median CD4 count at 
the time of TB diagnosis, which was available for 102 HIV/TB patients, was 76 cells/μL, 
with an interquartile range (IQR) of 26–199 cells/μL. By race, the median was 62 cells/μL 
for blacks and 134 for whites, with nearly identical interquartile ranges. While not 
statistically different, 45% of blacks had CD4 counts less than 50, compared with 33% of 
whites (OR=1.7, CI=.4–7.0).
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Timing of the TB/HIV diagnoses
For over 60% of the 81 TB patients with date of HIV diagnosis, the TB diagnosis occurred 
near the time of or before their HIV diagnosis. The majority of HIV/TB patients were 
diagnosed with HIV 3 months before (57%) or after (4%) TB diagnosis. Sixty-one percent 
of HIV-positive blacks had a late HIV diagnosis compared to 57% of whites; however, this 
difference was not statistically significant (OR=1.2, CI=.2–5.6). No characteristics were 
found to be significantly associated with a late HIV diagnosis (see Supplement).
TB-related mortality
Sixteen percent of the sample died; 16% of blacks and 17% of whites. Forty percent of 
deaths occurred prior to TB diagnosis, while 60% occurred during TB treatment. Twenty-
five percent of patients with HIV died, compared with 14% of persons without HIV. Among 
the 29 HIV/TB patients who died, 38% were diagnosed with TB after death, and 62% were 
alive at the time of TB diagnosis, but died in a median 38 (IQR=10–89) days after starting 
TB treatment.
Patients with HIV had greater odds of TB-associated mortality than patients without HIV 
(AOR=4.2, CI=2.2–8.1) (see Supplement). Greater odds of TB-associated mortality, from 
greatest to least, were also found for: persons with chronic illness (AOR=4.0, CI=1.5–10.6-), 
and for persons aged 65 or older (AOR=2.9, CI=1.6–5.3) (see Supplement).
Discussion
We conducted this study to assess the impact of HIV on black/white TB disparities among a 
sample of U.S.-born non-Hispanic TB patients. The sample had approximately a two-fold 
higher rate of HIV co-morbidity than among all U.S. TB patients, and consequently a greater 
mortality rate, which limit generalizability of study findings to the sites that were sampled: 
ten Eastern and Southern U.S. sites. We documented that a significantly higher proportion of 
black TB patients had HIV than of white TB patients. We also found that it was common for 
blacks as well as whites to receive their HIV diagnosis at a time that was too late for them to 
have benefitted from HIV treatment that could have prevented their TB; 61% of blacks and 
57% of whites received such “late” HIV diagnoses (a difference that was not statistically 
significant). While this is a secondary analysis of data collected in 2009 – 2010, it is the only 
known large multisite study to examine timing of HIV and TB diagnoses and 
immunosuppression, which are critical to understanding the risk of TB incidence and 
HIV/TB mortality. However a study specifically in California during the same period had 
similar findings.11 Since the NTSS does not include date of HIV diagnosis, CD4 counts or 
viral loads, or HIV antiretroviral treatment, studies such as this one are needed to assess 
disparities in HIV/TB and should be repeated, especially as HIV care increases with 
improved insurance coverage.12 HIV diagnosis and HIV treatment prior to exposure to TB 
can help prevent TB disease.13, 14, 15 The median CD4 count at TB diagnosis among persons 
with HIV in our study was less than 80 cells/μL, and only 40% of the HIV/TB patients were 
on three or more anti-retroviral medications (for an unknown length of time), both indicating 
that HIV was poorly managed in this population.
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We documented that tests for TB infection (i.e., TST or IGRA) were less likely to be 
positive for TB patients with HIV than for those without HIV, which is consistent with the 
literature.16 As continued evaluation for TB disease is recommended for HIV-positive 
patients despite negative TB infection results, knowledge of HIV status prior to TB 
screening is imperative for early diagnosis of TB disease.3
Nearly all the HIV/TB patients reported one or more TB symptoms, which could raise 
provider suspicion of TB disease and prompt additional testing for TB, resulting in more 
detected and treated TB cases. Typically, the next diagnostic test ordered when a patient 
reports pulmonary TB symptoms is a chest radiograph. However, pulmonary TB patients 
with HIV have reduced likelihood of cavitation on chest radiography,17 which was also 
documented in this study. NAATs can aid in rapidly diagnosing TB, but only 47% of TB 
patients in this study received a NAAT. CDC initially recommended NAAT in 1996 for use 
on (preferably) the first collected acid-fast-bacilli smear-positive specimen, and in January 
2009 for all (including smear-negative) specimens when TB disease is suspected.18 The use 
of NAAT is determined by providers, hospitals, and laboratories and must specifically be 
requested. NAAT has been recommended by the Infectious Diseases Society of America 
since at least 2004 for persons with HIV suspected of TB, because of the increased risk of 
TB transmission among a highly vulnerable population and of mortality from undiagnosed 
TB.3 In 2016, 62% of all reported U.S. TB cases had documentation of a NAAT, so there is 
still room for improvement.1
We also documented that HIV infection was independently associated with greater TB-
associated mortality. If blacks have greater odds of having HIV infection, and persons with 
HIV have greater odds of death, then prevention of mortality among blacks with HIV will 
depend on early access to HIV diagnosis and care. The largest proportion of blacks and the 
largest proportion of blacks with HIV in the United States reside in the South.5 Many states 
in the South have not expanded Medicaid eligibility, which likely affects access to healthcare 
for many. Insurance coverage for persons with HIV has been most affected by their 
exclusion for pre-existing conditions, high premiums, and by ineligibility for Medicaid.12 In 
a study comparing insurance coverage of persons with HIV in 2012 prior to implementation 
of the Affordable Care Act (ACA), with coverage in 2014 after ACA implementation, 
Medicaid coverage increased by 13% for whites and 11% for blacks in sampled states that 
expanded Medicaid, but did not increase significantly in sampled states that did not expand 
Medicaid.12 As of November 2017, five of the jurisdictions in this study have expanded 
Medicaid (Maryland, New Jersey, Pennsylvania, New York City and the District of 
Columbia) and five have not (Georgia, Tennessee, Texas, North Carolina, and Virginia).19 
Among blacks with known HIV infection in the United States, levels of HIV care and viral 
suppression are lower than for whites; in 2014, 68% of blacks received any HIV care, versus 
74% of whites.20
Limitations of our study include data collection and analysis at sites in the Eastern United 
States, which might not be representative of other locations. It is also possible that the black 
and white study participants who were interviewed might not be representative of all black 
and white TB patients at the study sites. However, a previous publication of study data 
reported that the 3:1 ratio of black to white study enrollees was maintained among 
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interviewees.21 Another limitation is that cause of death was not specifically ascertained 
from medical records; however a recent publication documented that 72% of deaths with TB 
are TB-related.22 While the study data are a bit old, the study required significant time to 
abstract data from multiple sources and to interview patients, study procedures which are not 
likely to be repeated in the near future.
Along with early HIV diagnosis and effective antiretroviral treatment, TB disease can be 
prevented by testing and treatment for TB infection.3,23 Testing for TB infection is 
recommended at HIV diagnosis and annually for persons who are at risk for TB exposure.3 
For persons with HIV, recommended treatment for latent TB infection (LTBI) is 9 months of 
isoniazid.3 For those on efavirenz or raltegravir-based HIV antiretroviral regimens, 4 months 
of rifampin or rifabutin, or 3 months of high-dose isoniazid and rifapentine (3HP) are 
alternative regimen choices.3,24 A large population-based study in 2010–2012 revealed that 
more than 30% of HIV-infected patients had never been tested for TB infection, so there is 
potential room for improvement.25
Conclusions
U.S.-born non-Hispanic black TB patients had a greater HIV prevalence than whites. While 
TB-associated mortality was associated with HIV, it was not significantly associated with 
black or white race. Most HIV/TB patients in this study were severely immunosuppressed 
(median CD4=75.5 cells/μL) and were not diagnosed with HIV until near the time that they 
were diagnosed with TB. Appropriate management of HIV infection through effective 
antiretroviral therapy results in a more immunocompetent patient who is less susceptible to 
progressing to TB disease. Improvements in HIV diagnosis and care, treatment for latent TB 
infection, and rapid TB diagnosis are all needed to reduce TB incidence and mortality in 
persons with HIV.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Percentage of Reported US-born TB Cases with HIV, Non-Hispanic Whites and Blacks, 
1994–2016*
*Data provided by CDC/DTBE Surveillance, Epidemiology, and Outbreak Investigations 
Branch, 12/19/2017. The numerator and denominator exclude all California cases from 1993 
– 2016, which only reported AIDS/TB case registry match data from 1993–2003 and did not 
report HIV/TB until 2011, and Rhode Island cases from 1993 – 1997 and Vermont cases 
from 2007 – 2010, neither of which reported HIV/TB to CDC during those periods.
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Table 1.
Characteristics of Study TB Patients With and Without HIV, 2009–2010, N=552
Characteristic
With HIV Without HIV Unadjusted Adjusted+
n Row % n Row %
Odds 
Ratio
95% Confidence 
Interval (CI)
Odds 
Ratio
95% Confidence 
Interval (CI)
118 21 434 79
Black* 108 25 318 75 3.9 2.0–7.8* 3.4 1.7–6.8*
White 10 8 116 92
Male 85 22 298 78 1.2 .7–1.8
Female 33 20 136 80
Age > 65* 7 6 109 94 0.2 .1–.4* 0.3 .1–.6*
Age < 65 111 25 325 74
< High School Education* 50 25 154 75 1.4 .9–2.2
> High School Education 61 19 266 81
 Unknown 7 14
Homeless* 34 37 59 63 2.6 1.6–4.2* 2.5 1.5–4.3*
Not homeless 83 18 375 82
 Unknown 1
Inmate* 8 29 20 71 1.5 .7–3.6
Not an inmate 102 21 395 79
 Unknown 8 19
Long-term care resident* 2 12 15 88 0.5 .1–2.3
Not a long-term care resident 105 21 399 79
 Unknown 11 20
Substance use* 53 31 116 69 2.3 1.5–3.5*
No substance use 62 17 307 83
 Unknown 3 11
*Significant at 95% confidence level
+Variables statistically significant at the 95% confidence level from backwards selection. The initial model included race, sex, age, education, 
homelessness, incarceration, long-term care residence, and substance use
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Table 2.
Clinical Characteristics of Study TB Patients With and Without HIV, 2009–2010, N=552
Characteristic With HIV Without HIV Unadjusted Adjusted+
n Column % n Column % Odds Ratio 95% CI Odds Ratio 95% CI
Chronic illness 87 75 333 78 0.9 .5–1.4
No chronic illness 29 25 95 22
 Unknown 2 6
Prior TB disease 11 10 17 4 2.5 1.1–5.6* 2.8 1.0–7.6*
No prior TB 104 90 406 96
 Unknown 3 11
Symptoms
Hemoptysis 16 15 61 15 1.0 .6–1.8
No hemoptysis 88 85 339 85
 Unknown 14 34
Chest pain 48 47 193 48 1.0 .6–1.5
No chest pain 54 53 209 52
 Unknown 16 32
Shortness of breath 63 62 218 54 1.3 .9–2.1
No shortness of breath 39 38 182 46
 Unknown 16 34
Cough 76 73 265 65 1.5 .9–2.4
No cough 28 27 143 35
 Unknown 14 26
Fever 62 60 183 45 0.6 .4–.9*
No fever 42 40 225 55
 Unknown 14 26
Night sweats 61 60 217 54 1.3 .8–2.0
No night sweats 41 40 183 46
 Unknown 16 34
Weight loss 77 81 257 69 1.9 1.1–3.3*
No weight loss 18 19 114 31
 Unknown 23 63
Swollen lymph nodes 34 35 64 16 2.8 1.7–4.6* 2.4 1.4–4.2*
No swollen lymph nodes 62 65 329 84
 Unknown 22 41
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Characteristic With HIV Without HIV Unadjusted Adjusted+
n Column % n Column % Odds Ratio 95% CI Odds Ratio 95% CI
Fatigue 63 64 216 55 1.4 .9–2.3
No fatigue 36 36 177 45
 Unknown 19 41
Any symptom 111 97 385 90 3.2 1.1–9.2*
No symptom 4 3 45 10
 Unknown 3 4
Diagnostics
Ever had a tuberculin skin test (TST) or
interferon gamma release assay (IGRA) 101 86 395 91 0.6 .3–1.1
No TST history 17 14 39 9
Ever had a positive TST, of those who
had a TST or IGRA 71 70 327 83 0.5 .3–.8*
No positive TST 30 30 68 17
Ever had a chest radiograph (CXR) 117 99 434 100 0.0
No CXR 1 1 0 0
Abnormal CXR, among those having a
CXR 111 96 411 95 1.2 .5–3.6
No abnormal 5 4 22 5
 Unknown 1 1
Cavitation on CXR, among those with
pulmonary TB 26 27 168 47 0.4 .3–.7*
No cavitation 71 73 191 53
7 13
Ever had a nucleic acid amplification
test (NAAT) 52 44 208 48 0.9 .6–1.3
No NAAT 66 56 226 52
Sites of disease
 Pulmonary only 75 64 332 76 0.5 .3–.8*
 Extrapulmonary only 10 8 56 13 0.6 .3–1.3
 Both pulmonary and extrapulmonary 31 26 41 9 3.5 2.0–5.8*
 Unknown 2 2 5 1
Outcome
Died, any non-accidental cause 29 25 59 14 2.1 1.3–3.4*
Alive 89 75 375 86
*Significant at 95% confidence level
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+Variables statistically significant at the 95% confidence level from backwards selection. The initial model included chronic illness, prior TB, and 
all symptoms
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